Accelerating End-to-End Safety Assessment Across Fragmented Data with Signals Agents

Gain the Decision Advantage

Breakthrough 2027 brings together life sciences leaders, industry regulators and experts, to explore the future of AI in life sciences.

Case Study

Accelerating End-to-End Safety Assessment Across Fragmented Data with Signals Agents

The signal and risk management landscape is rapidly evolving as artificial intelligence (AI) reshapes how organizations identify, evaluate, and respond to potential safety risks. Traditional manual methods are being replaced by AI, with intelligent agents speeding up insight generation while still supporting rigorous, evidence-based decision-making. Check out our case study to see how these conventional methods compare with an AI-enabled approach, and how Signals Agents, powered by NavaX, serves as an active intelligent partner that accelerates time-to-insight and enhances decision support across the signaling lifecycle.

View Now

LifeSphere® Technology is trusted by these industry leaders:

Let's Talk

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Get started!

First Name*

Last Name*

Email*

Job Title*

Company Name*

HQ Country*

Area of Interest*

Purchase Timeframe*

Mladen Prenc2026-09-15T10:02:21+00:00

ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 220 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.

Quick Links

Follow Us

Font resize

Contrast

Accessibility by WAH

Case Study

Accelerating End-to-End Safety Assessment Across Fragmented Data with Signals Agents

LifeSphere® Technology is trusted by these industry leaders:

Resources

Let's Talk

Get started!

Share This on LinkedIn